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Chromosomal instability is a hallmark of human cancer cells, but its role in carcinogenesis
remains poorly resolved. Insights into this role have emerged from studies on the tumour
suppressor BRCA2, whose inactivation in human cancers causes chromosomal instability
through the loss of essential functions of the BRCA2 protein in the normal mechanisms
responsible for the replication, repair and segregation of DNA during cell division. Humans
who carry heterozygous germline mutations in the BRCA2 gene are highly predisposed to
cancers of the breast, ovary, pancreas, prostate and other tissues. Here, we review recent
studies that describe genetically engineered mouse models (GEMMs) for pancreatic cancer
associated with BRCA2 mutations. These studies not only surprisingly show that BRCA2
does not follow the classical Knudson “two hit” paradigm for tumour suppression, but
also highlight features of the interplay between TP53 inactivation and carcinogenesis in
the context of BRCA2 deficiency. Thus, the models reveal novel aspects of cancer evolution
in carriers of germline BRCA2mutations, provide new insights into the tumour suppressive
role of BRCA2, and establish valuable new preclinical settings for testing approaches to
pancreatic cancer therapy; together, these features emphasize the value of GEMMs in can-
cer research.
ª 2013 Federation of European Biochemical Societies.
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nisms are perturbed by the genetic alterations associated
with cancer remains far less studied. Here, we will review
this question from the perspective of recent work using trans-
genicmodels designed to recapitulate a specific human cancer
involving mutations affecting the tumour suppressor gene
BRCA2, associated with hereditary predisposition to breast,
ovarian, pancreatic and other cancers. There is by now clear
evidence to implicate the large, 3418 residue BRCA2 protein
(3328 residues in the mouse) in the maintenance of chromo-
some integrity during cell division (Venkitaraman, 2009).
BRCA2-deficient cells accumulate structural chromosome ab-
errations as they divide, and also become aneuploid through
losses or gains in whole chromosomes (Gretarsdottir et al.,
1998; Patel et al., 1998; Tutt et al., 1999; Yu et al., 2000). A large
body of evidence connects the chromosomal instability
observed in BRCA2-deficient cells to essential biological func-
tions of the BRCA2 protein in DNA repair by homologous
recombination (Connor et al., 1997; Patel et al., 1998;
Moynahan et al., 2001), in progression through the S and G2/
M phases of the cell cycle (Lomonosov et al., 2003; Ayoub
et al., 2009; Menzel et al., 2011; Schlacher et al., 2011) and in
mitotic cell division by cytokinesis (Daniels et al., 2004;
Mondal et al., 2012). Thus, murine models that recapitulate
the effect of cancer-associated mutations in human BRCA2
on tissue-specific carcinogenesis provide an important oppor-
tunity to dissect the complex roles played by chromosomal
instability during human carcinogenesis.1. Modelling human pancreatic cancer associated
with BRCA2 inactivation
Pancreatic ductal adenocarcinoma (PDAC) represents the
fourth leading cause of cancer mortality worldwide, with an
incidence of approximately 217,000 new cases each year
nearly matched by 213,000 deaths (Parkin et al., 2001). Several
of the most frequent genetic events underlying the initiation
and progression of human pancreatic cancer have been iden-
tified (Hezel et al., 2006; Maitra and Hruban, 2008). These
include activating mutations in the KRAS proto-oncogene,
which occur in >90% of PDAC (Caldas and Kern, 1995) and
are considered as a key driver for pancreatic carcinogenesis,
and mutations inactivating the TP53 gene, which occur in
50e75% of patients (Redston et al., 1994).
Moreover, several lines of evidence implicate mutations
inactivating the BRCA2 tumour suppressor in an estimated
5e20% of familial PDAC (Hahn et al., 2003; Couch et al.,
2007). Germline carriers of deleterious BRCA2 mutations that
commonly truncate the encoded protein exhibit an increased
lifetime risk of developing PDAC, in addition to their well-
known predisposition to cancers of the breast and ovary
(Breast Cancer Linkage Consortium, 1999). Within high-risk
pancreatic cancer kindreds, inherited mutations in BRCA2
represent the most frequently encountered germline genetic
alteration (Hahn et al., 2003). The incidence of germline
BRCA2 mutations in apparently sporadic pancreatic cancers
may be as high as in breast or ovarian cancer (Goggins et al.,
1996). More recently, PALB2, which encodes a BRCA2-
interacting protein also essential for homology-directed DNArepair, has emerged as a pancreatic cancer susceptibility allele
(Jones et al., 2009).
Three new transgenic models for pancreatic adenocarci-
noma associated with BRCA2 inactivation have recently been
described (Skoulidis et al., 2010; Feldmann et al., 2011;
Rowley et al., 2011) [Figure 1]. One of these models does not
incorporate activation of the Kras oncogene (Feldmann et al.,
2011). In contrast, the other two models (Skoulidis et al.,
2010; Rowley et al., 2011) use a conditional gene-targeted allele
developed by Tuveson, Jacks and colleagues (Jackson et al.,
2001; Johnson et al., 2001), in which tissue-specific activation
of oncogenic KrasG12D is driven on a single allele by loxP-
CRE mediated recombination, mimicking a genetic event
that frequently triggers Kras activation in human cancers.
CRE recombinase expression is controlled by the PDX1 pro-
moter, which is expressed at E8.5 and required for organogen-
esis of the pancreas, whereby loss of the gene is associated
with an absence of pancreatic formation (Jonsson et al.,
1994; Offield et al., 1996). The expression of the PDX1-CRE
transgene therefore occurs throughout the pancreatic cellular
compartment, albeit in a stochastic manner, to trigger Kras
activation (Hingorani et al., 2003).
Patients who carry germline mutations affecting BRCA2
harbour the germline mutant allele in all somatic tissues,
whereas the second BRCA2 allele is wildtype (Wooster et al.,
1994). It has been widely believed that loss of the second,
wild-type BRCA2 allele in nascent cancer cells (termed ‘loss
of heterozygosity’ or LOH) is necessary for the emergence of
tumours in germlinemutation carriers. The pancreatic cancer
model developed in our laboratory (Skoulidis et al., 2010)
mimics this presumed sequence of events. It carries in all so-
matic tissues a truncated allele of murine Brca2 (Brca2Tr),
which truncates the gene in an evolutionarily conserved
and functionally critical region encoded by exon 11, resem-
bling deleterious germline mutations found in human car-
riers (Friedman et al., 1998). The second Brca2 allele, Brca2F11
(Jonkers et al., 2001) can be conditionally disrupted to remove
exon 11 by loxP-CRE recombination in the pancreas. This
event is driven by PDX1-CRE, and therefore occurs in the
same tissues which undergo Kras activation. There is evi-
dence that both the Brca2Tr and Brca2F11 alleles can express
a truncated protein product (Patel et al., 1998; Choi et al.,
2012), a point we will later return to. Notably, the models
developed by Rowley et al. and Feldmann et al. both exclu-
sively use a strain homozygous for the conditional Brca2F11
allele; thus, germline heterozygosity for BRCA2 is not
modelled in their experiments.
All three of the new pancreatic cancer models incorporate
conditional alleles that inactivate Tp53 in the pancreas, to
mimic the frequent loss of this tumour suppressor in human
pancreatic cancers. Somewhat different Tp53 alleles are used
by each group, an important distinction given that the nature
of Tp53mutations is thought to affect pancreatic cancer devel-
opment (Olive et al., 2004). Two of the studies employ gain-of-
functionmutants affecting a single allele. These are either the
structuralmutant Tp53R172H (Feldmann et al., 2011) or the con-
tact mutant Tp53R270H (Skoulidis et al., 2010). Both these Tp53
mutants are associated with the development of carcinomas
(Olive et al., 2004). In contrast, the third study uses a null allele
of Tp53, wherein exons 2e10 are deleted by PDX1-CRE
Figure 1 e Modelling the role of Brca2 in PDAC development. Key features and findings from the three genetically engineered mouse models
(GEMMs) are summarized here, and described in the main text. (A) Skoulidis et al. uniquely employ a truncated Brca2Tr allele mimicking germline
mutations in human mutation carriers expressed in all somatic tissues. In contrast, (B) Feldmann et al. and (C) Rowley et al. conditionally delete
Brca2 in the pancreas alone. All three GEMMs introduce tissue-specific alleles activating Kras or inactivating Trp53. It is important to note that
the Brca2 alleles as well as the Trp53 alleles used in each model are distinct.
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represents human cancer-associated mutations.
Thus, it should be clear from the foregoing that these three
recently-published models for pancreatic carcinogenesis
associated with BRCA2 inactivation harbour important differ-
ences not only in the tissue-specificity, nature and timing of
mutant Tp53 and Brca2 alleles, but also in the presence of
mutant Kras. We believe that these distinctions are vital to un-
derstanding the marked differences in pancreatic carcinogen-
esis observed in the studies, the key findings from which are
highlighted in Table 1.2. Brca2Tr heterozygosity suffices for pancreatic
carcinogenesis driven by mutant Kras
BRCA2 has been believed to follow the classical ‘two-hit’ para-
digm for tumour suppression (Smith et al., 1992; Collins et al.,
1995; Rahman and Stratton, 1998). Initial studies soon after the
discovery of BRCA2 reported consistent inactivation of the
wild-type BRCA2 allele through loss-of-heterozygosity (LOH)
in breast or ovarian cancer cells from mutation carriers
(Collins et al., 1995; Gudmundsson et al., 1995), engendering
thewidely accepted view that BRCA2 LOH is an essential event
in carcinogenesis. A few notes of dissent have emerged in
later studies (King et al., 2007; Willems et al., 2008), but they
have not gained widespread attention.
In this context, it is notable that the studies reported in
Skoulidis et al. unexpectedly reveal that BRCA2 heterozygosity
promotes pancreatic cancer development inmice andmen. In
both the Tp53wildtype and Tp53R270H cohorts from themurine
model, heterozygosity for Brca2 (through the Brca2Tr/Wt geno-
type) acts with KrasG12D to accelerate the progression andTable 1 e Comparison of the major phenotypes associated with Brca2-de
alleles, in the context of different initiating lesions. Possible mechanisms
Study Cohort
Skoulidis
et al., 2010
KrasG12D 15% tumour penetrance w
KrasG12D, Brca2Tr/Wt Accelerated tumourigene
KrasG12D, Brca2Tr/F11 Pancreatic insufficiency;
KrasG12D, Tp53R270H, Brca2Wt/Wt Highly penetrant tumour
KrasG12D, Tp53R270H, Brca2Tr/Wt Accelerated tumourigene
KrasG12D, Tp53R270H, Brca2Tr/F11 Further acceleration of tu
of PDAC development wi
Rowley
et al., 2011
KrasG12D 61% tumour penetrance w
KrasG12D, Brca2F11/Wt 66% tumour penetrance w
KrasG12D, Brca2F11/F11 Pancreatic insufficiency;
Brca2Wt/Wt No tumour formation
Brca2F11/Wt No tumour formation
Brca2F11/F11 No tumour formation
Tp53F2-10/F2-10, Brca2Wt/Wt Low tumour penetrance w
Tp53F2-10/F2-10, Brca2F11/Wt Similar penetrance of tum
Brca2F11/F11
Tp53F2-10/F2-10, Brca2F11/F11 Increased tumour penetr
of Brca2F11/Wt Mixed histo
remainder mucinous tum
Feldmann
et al., 2011
Brca2F11/F11 Pancreatic insufficiency;
15 months. Median surviv
Tp53R172H, Brca2F11/F11 Pancreatic insufficiency;
survival 375 days.development of PDAC. A similar conclusion is reached from
studies on a small number of human pancreatic cancer sam-
ples from carriers of the Icelandic founder mutation in
BRCA2, the allele BRCA2999Del5, which is 5 bp deletion in exon
9 that causes a frame-shift leading to the expression of a
very short and unstable protein product (Mikaelsdottir et al.,
2004). Three of the 4 cases tested do not exhibit LOH.
How heterozygosity for Brca2Trmay promote tumourigene-
sis remains uncertain. One possibility is that this genotype
causes a mutator phenotype, owing to defects in DNA repair
arising from a known role of BRCA2 in homologous DNA
recombination (Patel et al., 1998; Moynahan et al., 2001; Tutt
et al., 2001). However, previous studies on murine embryo fi-
broblasts (MEFs) heterozygous for Brca2Tr reveal no statisti-
cally significant effects on sensitivity to genotoxic agents
(Patel et al., 1998; Yu et al., 2000). Neither Brca2Tr/WT mice
(Friedman et al., 1998), nor strains heterozygous for other
Brca2 truncation mutants (Connor et al., 1997; Sharan et al.,
1997; Jonkers et al., 2001; Yan et al., 2004), exhibit cancer pre-
disposition. Notably, a lacZmutation reporter gene (Boerrigter
et al., 1995) incorporated into the germline of mice heterozy-
gous for a Brca2 truncation similar but not identical to Brca2Tr
(Tutt et al., 2002) reveals no evident mutator phenotype. On
the other hand, MEFs from this strain showed a mild alter-
ation in DNA repair kinetics during recovery from 4Gy of
ionizing radiation. Thus, there is little convincing evidence
that heterozygosity for these Brca2 mutant alleles creates a
DNA repair defect that could explain heightened cancer pre-
disposition, although the possibility has not yet been conclu-
sively excluded.
In this connection, it is important to note that these
cellular approaches do not yet account for the cooperative ef-
fect of mutant Kras on pancreatic carcinogenesis associatedficient PDAC in three GEMMs. Each model employs distinct Brca2
underlying the variations in phenotype are discussed in the main text.
Associated phenotype
ith long latency; 100% PDAC
sis with an increase in tumour penetrance at 30%; 100% PDAC
some tumours develop but with long latency; 100% PDAC
formation with a median survival of 168 days; 100% PDAC
sis, median survival 143 days, in comparison to Brca2Wt; 100% PDAC
mourigenesis, median survival 84 days, all tumours showed regions
th noted regions of Acinar histology in 18% of cases
ith median survival 406 days
ith median survival 366 days- similar to Brca2Wt
13% tumour penetrance with long latency
ith acinar histology
our formation to Brca2Wt but with the associated histology of
ance and acceleration of tumour formation in comparison to Brca2Wt
logy: PDAC 40%, Acinar 15%, high-grade undifferentiated 35%,
ours. Median survival 300 days.
development of PDAC but with incomplete penetrance (w15%) at
al 454 days.
highly penetrant PDAC formation (100%) at 15 months. Median
MO L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 1 6 1e1 6 8 165with Brca2 heterozygosity, as suggested by the murine model
developed by Skoulidis et al. Even a subtle increase in muta-
tional load induced by Brca2 heterozygosity in mutant Kras
expressing cells ewhich might be undetectable in cellular ex-
periments, but significant in vivo e could plausibly accelerate
the progression of pre-malignant pancreatic intra-epithelial
(PanIN) lesions (which occur frequently even in apparently
normal pancreatic parenchyma (Hruban et al., 2008)) to overt
malignancy. Further studies addressing this issue in murine
models are clearly warranted.
Whether different BRCA2 alleles behave in a manner
similar to Brca2Tr is not clear. Like Brca2Tr, heterozygosity for
BRCA2999Del5 apparently suffices to predispose human carriers
to pancreatic carcinogenesis. However, the instability of the
truncated protein encoded by BRCA2999Del5 (Mikaelsdottir
et al., 2004) suggests that haploinsufficiency for BRCA2 (as
opposed to any trans-dominant effect of a mutant BRCA2 pro-
tein) accounts for the phenotypic effects of heterozygosity in
patients who carry this Icelandic founder mutation. In
contrast, Rowley et al. describe no heterozygous effect in
any of their Brca2F11/Wt cohorts despite the presence ofmutant
KrasG12D. Interpretation of this difference is not straightfor-
ward, since the Brca2F11 allele engenders Brca2 loss only in
the cells expressing PDX1-CRE, unlike Brca2Tr, which is
expressed in all somatic cells. This raises the possibility that
non-cell autonomous effects of Brca2F11 heterozygosity e for
example on stromal cells rather than the nascent cancer cells
e may account for the cancer-predisposing effect of the
Brca2Tr allele.
Mitotic functions have also been ascribed to BRCA2, and
interestingly, defects in G2 checkpoint function (Menzel
et al., 2011), mitotic checkpoint enforcement (Choi et al.,
2012) and the completion of cell division by cytokinesis
(Daniels et al., 2004; Shive et al., 2010; Jonsdottir et al., 2012;
Mondal et al., 2012) have been reported in BRCA2-deficient
cells.Whether or not these roles for BRCA2may explain the ef-
fect of heterozygosity in tumour development is yet to be
explored. Heterozygosity for the Brca2Tr allele is enough to
trigger cytokinetic defects in MEFs (Daniels et al., 2004), but
it is unclear whether the othermitotic functions are perturbed
by BRCA2 heterozygosity.
Importantly, recent data from human studies further sup-
port that BRCA2 heterozygosity is enough to promote carcino-
genesis. In breast cancers, incomplete loss of the remaining
wild-type allele has been observed using techniques more
sensitive than those applied in the original studies (King
et al., 2007). Importantly large-scale, unbiased genomic
sequencing of high-grade serous ovarian carcinomas high-
lighted the retention of the wild-type allele in end stage dis-
ease from w25% of germline Brca2 carriers (Atlas, 2011).
Furthermore, a detailed study of prostate tumour progression
in BRCA2 germline mutation carriers uncovered no LOH in
high-grade prostatic intraepithelial neoplasias, considered
precursor lesions to the development of prostate adenocarci-
noma, and up to 55% of the malignant tumours analysed
(Willems-Jones et al., 2012). Collectively, these data suggest
that cancers arising in germline BRCA2 mutation carriers
frequently fail to exhibit loss of the wildtype allele, and
that failure to exhibit LOH occurs in BRCA2-mutant cancers
from several different tissues. Thus, BRCA2 may not followthe classical Knudson “two hit” paradigm for tumour
suppression.
Interestingly, these conclusions can be set against the
emerging backdrop of ongoing studies on tissue samples
from patients with familial forms of pancreatic cancer. A
study of 58 pancreatic intra-epithelial neoplasms and intra-
ductal papillary mucinous neoplasms reveals that somatic
losses in BRCA2 copy number are infrequent (Hong et al.,
2012). However, definitive evidence addressing the extent to
which the lessons from GEMMs of Brca2-deficient pancreatic
cancers can be applied to human neoplasia awaits the results
of more extensive genome sequencing studies on pancreatic
cancer samples from patients harbouring germline BRCA2
mutations.3. Pancreatic cancer histopathology and BRCA2
genotype
Murine pancreatic cancers emerging in Brca2Tr/F11 strains in
which both Brca2 alleles are inactivated in PDX1-CRE express-
ing cells exhibit a preponderance of acinar cell carcinoma his-
tology. Correspondingly, 3 of the four human pancreatic
cancers from BRCA2999Del5 mutation carriers that exhibited
LOH were also of the acinar type (Skoulidis et al., 2010), which
normally accounts for only 1e2%% of human pancreatic can-
cers (Hruban, 2007). This raises the possibility that these geno-
types promote the evolution of acinar cell carcinomas rather
than PDAC. Rowley et al. (2011) also observe differences in
the histopathological spectrum of pancreatic malignancies
frommice inwhich Brca2 aswell as Tp53 had been inactivated,
when compared to Tp53 deficiency alone. These observations
raise the possibility that the nature of Brca2 mutations, their
timing, or their coincidence with alterations with Tp53 may
alter the histopathological evolution of pancreatic cancers in
mice. However, these observations remain too limited to allow
firm conclusions to be drawn, and we draw attention to them
here simply to emphasize the need for further studies.4. Checkpoint inactivation, Tp53 mutations, and the
evolution of cancers following Brca2 inactivation
We and others have shown (Patel et al., 1998; Lee et al., 1999;
Tutt et al., 1999) that the genome-wide DNA damage that fol-
lows homozygous inactivation of BRCA2 leads to checkpoint
activation and cell cycle arrest, rather than the unrestrained
cellular proliferation typical of cancer. We have previously
proposed (Venkitaraman, 2009) that checkpoint inactivation
may therefore be an essential pre-requisite for homozygous
BRCA2 inactivation through LOH during carcinogenesis. The
work of Skoulidis et al. provides strong in vivo evidence for
this hypothesis, supported by the observations of Rowley
et al. In both murinemodels, bi-allelic Brca2 inactivation by it-
self leads to a loss of exocrine pancreatic parenchyma, a
concomitant increase in adipose tissue, and progressive loss
of organ functionality. Skoulidis et al. further demonstrate
that pancreatic insufficiency is preceded by the widespread
occurrence of DNA double-strand breakage marked by
gH2AX staining in cells lacking both copies of Brca2. Moreover,
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tant inactivation of Tp53 function prevents pancreatic insuffi-
ciency, and allows rapid PDAC development, in the pancreas
of mice carrying bi-allelic mutations inactivating Brca2.
When the observations from these studies are synthesized,
a picture emerges wherein BRCA2 heterozygosity in germline
mutation carriers may suffice to allow the development of
Kras-driven PDAC. Later inactivation of Tp53 or other check-
point genes may then allow eventual loss of the second
BRCA2 allele: although LOH is not an obligate step, it may pro-
mote the emergence of advanced cancers. Indeed, inferences
from a very small study of just 5 samples from human pancre-
atic cancer patients support such a scenario, although it re-
mains to be firmly established.5. Mouse models for PDAC associated with BRCA2
inactivation: lessons for cancer therapy
The work of Skoulidis et al. has implications for cancer ther-
apy. As discussed above, our results suggest that Brca2 hetero-
zygosity suffices for PDAC formation driven by mutant Kras in
mice and men. However, the rationale for the use of targeted
agents such as PARP1 inhibitors (PARP1i) in BRCA2-deficient
cancers is contingent upon bi-allelic BRCA2 inactivation in
the tumour cells (Bryant et al., 2005; Farmer et al., 2005).
Therefore, as confirmed in our work (Skoulidis et al., 2010),
PDAC cells that retain a functional Brca2 allele are resistant
to PARPi such as the AstraZeneca compound Olaparib. Thus,
PARP1 inhibitors should be reserved for clinical use when
BRCA2 LOH can be verified in the tumour, assessment of
which emerges as a critical requirement in the design of hu-
man clinical trials for the treatment of BRCA2-deficient
cancers.
These findings exemplify how the new generation of
GEMMs for PDAC may represent valuable surrogate models
for preclinical tests of therapeutic efficacy in patients. Impor-
tantly, such models not only allow in vivo proof of new thera-
peutic concepts, but may also provide a platform to assess the
pharmacodynamic and pharmacokinetic properties of new
agents, although species-specific differences may limit such
interpretations. The models also provide a flexible method
to assess the impact of therapy on tumour progression using
adapted multimodal imaging and drug bioavailability
(including tissue drug penetrance) analyses. An important
feature that determines if a particular GEMM is useful as a pre-
clinical platform is if the model recapitulates a similar clinical
response to standard therapy agents in clinical use in human.
For instance, the KPCmouse model is relatively unaffected by
gemcitabine similar to the small clinical benefit from this
agent in the advanced pancreatic cancer setting in humans
(Olive et al., 2009).
Each GEMM can be likened to a patient with a particular
tumour type, and hence, can be enrolled into preclinical trial
of novel agents (Eklund et al., 2013; Guerra and Barbacid,
2013). Such trials are facilitated by the use of adapted imaging
techniques to monitor for tumour development and progres-
sion. Such utility is beginning to have an impact in the clinical
setting. In humans, early phase clinical trials have shown
promise for the combination of nanoparticle albumin-linkedpaclitaxel (nab-paclitaxel) and gemcitabine in advanced
PDAC. Frese and colleagues have used the KPC mouse model
of pancreatic cancer to provide a mechanistic understanding
of the synergistic effect of this combination. Paclitaxel ap-
pears to inhibit the breakdown of gemcitabine throughmodu-
lation of a degradative enzyme, cytidine deaminase through a
reactive oxygen species-dependent pathway (Frese et al.,
2012). Such mechanistic analyses may help to rationalize
our clinical strategy of using such drug combination. For
instance, the nab-paclitaxel can be used as an inducting agent
followed by gemcitabine to enhance the tumouricidal effect of
the latter.
Rational clinical trials in man are likely to benefit from the
incorporation of an in vivo component that provides relatively
rapid feedback of the predicted response to new agents. The
preclinical assessment using GEMMs can either be used to
screen potentially useful therapeutic agents before progress-
ing to clinical trials, or alternatively, to critically assess the
mechanisms of action in vivo once an agent has been found
to be effective in a small-scale trial, before progressing to
larger Phase III clinical trial. One potential advantage of such
GEMMs is that unlike human trials, they will allow sequential
sampling of appropriate tumour tissues to assess the pharma-
codynamic impact of a particular agent. In pancreatic cancer,
several novel agents targeting a diverse range of molecular
pathways have been tested in GEMMs to complement early
phase clinical trials (Olive et al., 2009; Plentz et al., 2009;
Cook et al., 2012; Jacobetz et al., 2012). The results of these tri-
als will in due course affirm or refute the value of PDAC
GEMMs as a predictive tool for clinical efficacy in human
cancers.
The potential value of PDAC GEMMs as surrogates for the
preclinical testing of new therapies is critically dependent
on how closely these models mimic human PDAC. Several
studies (Hingorani et al., 2003; Tuveson and Hingorani, 2005;
Olive et al., 2009; Plentz et al., 2009; Cook et al., 2012) have
emphasized the similarities in histopathology, cancer pro-
gression, clinical behaviour and even drug pharmacody-
namics between PDAC GEMMs and human PDACs. However,
it remains unclear whether the spectrum of genetic alter-
ations is similar. Initial observations suggest that murine
KPC PDACs bear resemblance to the human disease insofar
as they exhibit a high degree of genomic instability, evident
from multiple non-reciprocal chromosomal translocations
(Hingorani et al., 2005). However, with emerging data from
large-scale sequencing of human PDAC tumours (Biankin
et al., 2012), it is now imperative that we further validate the
GEMMs at the genomic level to compare the genomic land-
scapes of murine and human tumours.
Because PDAC GEMMs incorporate high-penetrance ge-
netic events such as initiating oncogenes or inactivated
tumour suppressor genes from an early stage in a large num-
ber of susceptible cells, the resulting stereotypy of the malig-
nancies arising therein may not reflect the heterogeneity
likely to be present in human cancers. Importantly, the ge-
netic heterogeneity of human cancers may give rise to
differing therapeutic responses to any particular agent due
to the differing genetic and epigenetic signatures of the con-
stituent cells. It is conceivable that individual tumours can
take differing genetic ‘routes’ to achieve tumoural
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sions and secondary genetic hits that occur stochastically. It
is presumed that through inactivation of genes involved in
maintaining genomic stability (e.g. BRCA2 in models of
pancreatic cancer) may promote the stochastic acquisition
of genetic and consequent morphologic heterogeneity due to
the expected increase in mutation rate. However, this point
remains to be established in future studies, and also has
important implications for the potential value of GEMM
models in testing new therapeutic approaches against PDAC.
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